Trial Profile
Phase II study of amrubicin combined with carboplatin for refractory relapsed small-cell lung cancer.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 19 Oct 2012
Price :
$35
*
At a glance
- Drugs Amrubicin (Primary) ; Carboplatin (Primary)
- Indications Small cell lung cancer
- Focus Therapeutic Use
- 12 Oct 2012 Status changed from active, no longer recruiting to completed as reported by University Hospital Medical Information Network - Japan.
- 13 Oct 2011 New trial record